Interview 23 Nov 2022
What recent mixed clinical results can teach about Alzheimer’s disease
2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon, explains the lessons these events provide. The quest for a…